WO2001028365A1 - Supplement nutritionnel - Google Patents
Supplement nutritionnel Download PDFInfo
- Publication number
- WO2001028365A1 WO2001028365A1 PCT/FI2000/000899 FI0000899W WO0128365A1 WO 2001028365 A1 WO2001028365 A1 WO 2001028365A1 FI 0000899 W FI0000899 W FI 0000899W WO 0128365 A1 WO0128365 A1 WO 0128365A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- folate
- composition
- folic acid
- matter
- subject
- Prior art date
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 85
- 235000019152 folic acid Nutrition 0.000 claims abstract description 60
- 239000011724 folic acid Substances 0.000 claims abstract description 60
- 229940014144 folate Drugs 0.000 claims abstract description 35
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229960000304 folic acid Drugs 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 13
- 239000000126 substance Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 12
- 235000013305 food Nutrition 0.000 claims abstract description 11
- 239000000047 product Substances 0.000 claims abstract description 11
- 235000018823 dietary intake Nutrition 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 239000013543 active substance Substances 0.000 claims abstract description 4
- 230000002708 enhancing effect Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000013589 supplement Substances 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 2
- 235000015173 baked goods and baking mixes Nutrition 0.000 claims description 2
- 238000005728 strengthening Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 19
- 102000006996 Aryldialkylphosphatase Human genes 0.000 description 18
- 108010008184 Aryldialkylphosphatase Proteins 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 15
- 108010010234 HDL Lipoproteins Proteins 0.000 description 8
- 102000015779 HDL Lipoproteins Human genes 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 208000029078 coronary artery disease Diseases 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- -1 folinic acid Chemical compound 0.000 description 3
- 235000008191 folinic acid Nutrition 0.000 description 3
- 239000011672 folinic acid Substances 0.000 description 3
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 3
- 229960001691 leucovorin Drugs 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- WYMSBXTXOHUIGT-UHFFFAOYSA-N paraoxon Chemical compound CCOP(=O)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 WYMSBXTXOHUIGT-UHFFFAOYSA-N 0.000 description 2
- 229960004623 paraoxon Drugs 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 108010009043 arylesterase Proteins 0.000 description 1
- 102000028848 arylesterase Human genes 0.000 description 1
- 230000000778 atheroprotective effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000003929 folic acid group Chemical group 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a novel use of folic acid or folate, or of a functionally equivalent substance having the biochemical activity of folic acid or folate, such as folinic acid, as a dietary supplement in or for fortification of compositions of matter, such as products for ingestion or dietary intake, for example food and feedstuff s.
- the human serum paraoxonase is an antioxidative enzyme in high density lipoproteins (HDL), which eliminates lipid soluble radicals in the circulation and protects against coronary disease .
- HDL high density lipoproteins
- CHD coronary heart disease
- Paraoxonase/ arylesterase has been suggested to account for an important part of the antioxidative property of HDL 5 .
- a lowered PON activity has been reported also in patients with myocardial infarction (MI) 2"3 .
- the present invention is based on the finding that there is a positive correlation between circulating folate or dietary folate intake and enhanced serum PON activity.
- Enhanced serum PON activity improves the endogenous antioxidative capacity and defences of a subject, e.g. a human, thus reducing the risk e.g. for CHD, cancer, type II diabetes and cataract, and is also associated with the process of aging.
- the invention is directed to a method for enhancing the endogenous antioxidative defences of the body by dietary folic acid or folate supplementation.
- folate refers to the salts and esters of folic acid. Acceptable salts include i.e. the alkali metal salts, such as the sodium salt and the methylglucamine salt. Esters of folic acid can be prepared in a manner known to the person skilled in the art.
- the object of the invention is thus a method for the manufacture of a composition of matter for dietary intake with antioxidative defences enhancing effect, according to which method, in the said composition, folic acid or folate or a functionally equivalent substance is used as the active or effective agent.
- the object of the invention is the use of folic acid or folate or a functionally equivalent substance as a supplement or additive for the manufacture of a composition of matter for dietary intake with antioxidative defences enhancing effect.
- the object of the invention is a method for enhancing the antioxidative defences in a subject comprising administering, e.g. orally or parenterally, to said subject, an effective amount of folic acid or folate or a functionally equivalent substance.
- a functionally equivalent substance of folic acid or folate is intended to mean a substance that has the biochemical activity of folic acid, for example folinic acid or a salt or ester of folinic acid.
- subject means here a mammal, such as a human, or an animal, especially livestock or farm animals.
- the term "effective amount” means an amount of the active agent which after administration is sufficient to enhance the serum paraoxonase activity and thus the antioxidative defences in the subject.
- folic acid and folate can be used interchangeably.
- the composition of matter can be any dietary, typically orally administered composition, preparation or product, such as a food or feed product, food supplement, a drug preparation, or a raw material for such a product.
- the product to be used as the composition of matter to be supplemented or fortified by adding thereto folic acid or folate or a functionally equivalent its derivative can in principle be any type of food or feed product.
- folic acid or its derivative in any type of food or feed product, in which it can be properly included and distributed, such as processed foods, for example meat products, such as sausages, or also other ready made foods.
- dairy products such as milk, cheese, butter and youghurt
- other beverages such as fruit drinks and juices
- a dietary supplement can also be in the form of tablets, capsules, lozenges, granules, syrups, solutions, suspensions for oral administration, wherein the folic acid or folate is suitably included together with a carrier or filler substance, such as lactose, silica, glucose, starch, glycerol, diluents and solvents.
- a carrier or filler substance such as lactose, silica, glucose, starch, glycerol, diluents and solvents.
- dosage forms may include conventional additives such as glidants, stabilizer, colouring agents, preservatives, taste improving agents as well as a matrix to slow down absorption such as methyl cellulose or microcrystalline cellulose with colloidal anhydrous silica.
- the amount of folic acid or the functionally equivalent substance to be included in a composition of matter for dietary intake can vary broadly depending on the type of product to be supplemented or fortified, as well as on its intake frequency and intake levels. Such amounts can easily be determined by the person skilled in the art, to provide for and secure a suitable daily total intake of the dietary supplement.
- a typical amount for intake would be for example 15 to 1200 ⁇ g of folate per day for a subject of normal size, such as a human subject of appr. 80 kg, or a daily intake ranging from appr. 0.2 to 15 ⁇ g per kg body weight. This amount can be administered for example in bread, such as in 100 g of bread constituting a suitable single portion.
- Serum PON enzyme activity was analyzed based on its capacity to hydrolyze paraoxon, and erythrocyte folate levels were measured by RIA.
- erythrocyte folate levels were measured by RIA.
- KIHD Kuopio Ischaemic Heart Disease Risk Factor Study
- the unadjusted mean (95 % confidence interval (CI)) serum PON activity was 26.3 % lower (63.2, 47.5 to 79.0 nmol/mL/min) in the lowest fifth of erythrocyte folate concentration than in the highest fifth (85.7, 63.2 to 108.2 nmol/mL/min).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
Abstract
La présente invention concerne un procédé destiné à la fabrication d'une composition de matière servant comme apport alimentaire, telle qu'un aliment ou un produit alimentaire ou un supplément nutritionnel, destinée à renforcer le système de défense à effet antioxydant d'un sujet, tel qu'un être humain. Ce procédé est caractérisé par le fait qu'un acide folique, un folate, ou une substance dont la fonction est équivalente, est ajouté à la composition comme agent actif.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00969600A EP1221868A1 (fr) | 1999-10-18 | 2000-10-17 | Supplement nutritionnel |
| AU79272/00A AU7927200A (en) | 1999-10-18 | 2000-10-17 | Dietary supplement |
| JP2001530969A JP2003511097A (ja) | 1999-10-18 | 2000-10-17 | 栄養補助剤 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI992239A FI19992239A (fi) | 1999-10-18 | 1999-10-18 | Ravintotäydennys |
| FI19992239 | 1999-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2001028365A1 true WO2001028365A1 (fr) | 2001-04-26 |
Family
ID=8555463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/FI2000/000899 WO2001028365A1 (fr) | 1999-10-18 | 2000-10-17 | Supplement nutritionnel |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1221868A1 (fr) |
| JP (1) | JP2003511097A (fr) |
| AU (1) | AU7927200A (fr) |
| FI (1) | FI19992239A (fr) |
| WO (1) | WO2001028365A1 (fr) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001085178A1 (fr) * | 2000-05-08 | 2001-11-15 | N.V. Nutricia | Preparation nutritionnelle comprenant du ribose et de l'acide folique, et utilisation medicale associee |
| WO2002074230A2 (fr) * | 2001-03-20 | 2002-09-26 | Oy Jurilab Ltd | Molecule d'adn codant pour une variante de paraoxonase et utilisations correspondantes |
| WO2004066755A1 (fr) * | 2003-01-16 | 2004-08-12 | Esa Patentverwertungsa Gentur Sachsen-Anhalt Gmbh | Procede de production de saucisses crues par un processus de maturation accelere |
| ES2302571A1 (es) * | 2005-03-18 | 2008-07-16 | Universidad Complutense De Madrid | Procedimiento de obtencion de embutidos cocidos enriquecidos con acido folico. |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0595005A1 (fr) * | 1992-09-14 | 1994-05-04 | Vesta Medicines (Proprietary) Limited | Compositions pharmaceutiques pour diminuer des taux de homocystéine contenant de la vitamine B6, de l'acide folique et de la vitamine B12 |
| WO1997014422A1 (fr) * | 1995-10-17 | 1997-04-24 | Herbert Victor D | Composition a complement vitaminique multiple |
| DE29808384U1 (de) * | 1998-05-08 | 1998-08-06 | Eckes-Granini GmbH & Co. KG, 55268 Nieder-Olm | Getränk |
| US6121249A (en) * | 1998-07-01 | 2000-09-19 | Donald L. Weissman | Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins |
-
1999
- 1999-10-18 FI FI992239A patent/FI19992239A/fi unknown
-
2000
- 2000-10-17 AU AU79272/00A patent/AU7927200A/en not_active Abandoned
- 2000-10-17 WO PCT/FI2000/000899 patent/WO2001028365A1/fr not_active Application Discontinuation
- 2000-10-17 JP JP2001530969A patent/JP2003511097A/ja not_active Withdrawn
- 2000-10-17 EP EP00969600A patent/EP1221868A1/fr not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0595005A1 (fr) * | 1992-09-14 | 1994-05-04 | Vesta Medicines (Proprietary) Limited | Compositions pharmaceutiques pour diminuer des taux de homocystéine contenant de la vitamine B6, de l'acide folique et de la vitamine B12 |
| WO1997014422A1 (fr) * | 1995-10-17 | 1997-04-24 | Herbert Victor D | Composition a complement vitaminique multiple |
| DE29808384U1 (de) * | 1998-05-08 | 1998-08-06 | Eckes-Granini GmbH & Co. KG, 55268 Nieder-Olm | Getränk |
| US6121249A (en) * | 1998-07-01 | 2000-09-19 | Donald L. Weissman | Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins |
Non-Patent Citations (4)
| Title |
|---|
| DATABASE CAPLUS [online] HSU YU-CHIN ET AL.: "Effects of marginal folate deficiency on folate status, antioxidant capacity and lipid peroxidation in F344 rat livers", XP002954907, accession no. STN International Database accession no. 2000:89946 * |
| DATABASE CAPLUS [online] PFOHL MARTIN ET AL.: "Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease and myocardial infarction in type 2 diabetes", XP002954908, accession no. STN International Database accession no. 1999:158555 * |
| DIABETES, vol. 48, no. 3, 1999, pages 623 - 627 * |
| ZHONGHUA MINGUO YINGYANG XUEHUI ZAZHI, vol. 24, no. 3, 1999, pages 228 - 240 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001085178A1 (fr) * | 2000-05-08 | 2001-11-15 | N.V. Nutricia | Preparation nutritionnelle comprenant du ribose et de l'acide folique, et utilisation medicale associee |
| US6420342B1 (en) | 2000-05-08 | 2002-07-16 | N.V. Nutricia | Nutritional preparation comprising ribose and medical use thereof |
| US6548483B2 (en) | 2000-05-08 | 2003-04-15 | N.V. Nutricia | Nutritional preparation comprising ribose and medical use thereof |
| WO2002074230A2 (fr) * | 2001-03-20 | 2002-09-26 | Oy Jurilab Ltd | Molecule d'adn codant pour une variante de paraoxonase et utilisations correspondantes |
| WO2002074230A3 (fr) * | 2001-03-20 | 2003-04-03 | Jurilab Ltd Oy | Molecule d'adn codant pour une variante de paraoxonase et utilisations correspondantes |
| US6740746B2 (en) | 2001-03-20 | 2004-05-25 | Oy Jurilab Ltd. | DNA molecule encoding a variant paraoxonase and uses thereof |
| US7211387B2 (en) | 2001-03-20 | 2007-05-01 | Oy Jurilab Ltd. | DNA molecule encoding a variant paraoxonase and uses thereof |
| WO2004066755A1 (fr) * | 2003-01-16 | 2004-08-12 | Esa Patentverwertungsa Gentur Sachsen-Anhalt Gmbh | Procede de production de saucisses crues par un processus de maturation accelere |
| US7985436B2 (en) | 2003-01-16 | 2011-07-26 | Zylum Beteiligungsgesellschaft Mbh & Co. Patente Ii Kg | Method of producing raw sausage, comprising an accelerated maturing process |
| ES2302571A1 (es) * | 2005-03-18 | 2008-07-16 | Universidad Complutense De Madrid | Procedimiento de obtencion de embutidos cocidos enriquecidos con acido folico. |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1221868A1 (fr) | 2002-07-17 |
| FI19992239A (fi) | 2001-04-19 |
| AU7927200A (en) | 2001-04-30 |
| JP2003511097A (ja) | 2003-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9872844B2 (en) | Compositions and methods for the reduction or prevention of hepatic steatosis | |
| US6479069B1 (en) | Nutritional supplement for increased energy and stamina | |
| US11547736B2 (en) | Sauvignon blanc grape seed products for nonalcoholic fatty liver disease | |
| US7968529B2 (en) | Use of sphingolipids for reducing high plasma cholesterol and high triacylglycerol levels | |
| WO2012097064A1 (fr) | Compositions nutritionnelles et procédés pour contrôler le glucose dans le sang | |
| JP2009525990A (ja) | 医薬組成物 | |
| WO2012097061A1 (fr) | Compositions nutritionnelles et procédés pour améliorer le métabolisme protéique des muscles squelettiques | |
| EA025256B1 (ru) | Композиция, подходящая для лечения нарушений липидного обмена | |
| KR20210135551A (ko) | 개선된 생체이용률을 갖는 중쇄 트리글리세라이드 제제 및 이와 관련된 방법 | |
| US6265391B1 (en) | Method for preventing peripheral nerve damage | |
| US20220387464A1 (en) | Inositol phosphate-containing composition | |
| WO2017040407A1 (fr) | Compositions et procédés destinés à réduire ou à prévenir la stéatohépatite non alcoolique (shna) | |
| JP2022169385A (ja) | タモギタケ又はその処理物を有効成分として含む、脂質代謝改善剤 | |
| EP1221868A1 (fr) | Supplement nutritionnel | |
| JP2008156264A (ja) | ルイボスティーの食後高血糖および血中尿酸低下作用 | |
| CN115038435A (zh) | 肥胖抑制用组合物 | |
| US20100028457A1 (en) | Agent for prevention or treatment of blood glucose level elevation | |
| EP0595006A1 (fr) | Compositions pharmaceutiques et diététiques contenant de la vitamin B6, de l'acide folique et de la vitamine B12 pour le traitement des maladies métaboliques des enfants | |
| JPWO2008136173A1 (ja) | スチルベン誘導体を有効成分とする脂肪細胞分化抑制剤 | |
| JP2009173640A (ja) | ホモシステイン低下用組成物 | |
| KR101699123B1 (ko) | 코르티코스테론 저하용 조성물 | |
| Ashfield-Watt et al. | Folate, homocysteine, and heart drsease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2000969600 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 530969 Kind code of ref document: A Format of ref document f/p: F |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 10110322 Country of ref document: US |
|
| WWP | Wipo information: published in national office |
Ref document number: 2000969600 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 2000969600 Country of ref document: EP |